FIELD: medicine.
SUBSTANCE: invention refers to medicine and molecular biology. Essence of the invention is that for the purpose of detecting antibodies belonging to different classes of immunoglobulins, in blood serum or plasma of patients with COVID-19 or infected with said virus, uses a complex of antigenic recombinant proteins (RBD-SD1 and NTD fragments of spike-protein of SARS-CoV-2 virus, as well as nucleoprotein of SARS-CoV-2 virus, obtained on the basis of artificially synthesized genetic structures in plasmid DHFRControlTemplate, incorporated into strain BL21 (DE3) E.coli. Target recombinant proteins are sorbed in the pits of the folding polystyrene microplates, based on which the test system is formed, including four sets of reagents for both total and separate determination of IgM-, IgG-, IgA-antibodies to SARS-CoV-2 in laboratory diagnostics and clinical-epidemiological monitoring of COVID-19. Invention can be used for producing test systems for serological diagnosis of COVID-19 in order to assess the humoral immune response in infected individuals and epidemiological characteristics of the infectious process in the population, and in the future – to determine the effectiveness of vaccination and immunotherapy when obtaining and implementing the corresponding therapeutic and preventive preparations against SARS-CoV-2.
EFFECT: invention provides complete and comprehensive assessment of the immune response to SARS-CoV-2.
10 cl, 5 dwg, 1 tbl, 3 annexes
| Title | Year | Author | Number |
|---|---|---|---|
| STRAIN OF HCOV-19/RUSSIA/OMSK-202118-1707/2020 OF SARS-COV-2 CORONAVIRUS, IMMUNOSORBENT CONTAINING PURIFIED WHOLE VIRION ANTIGEN OBTAINED ON BASIS OF SPECIFIED STRAIN AND ISA TEST SYSTEM FOR DETECTING ANTIBODIES OF CLASSES M, G AND A TO SARS CORONAVIRUS-COV-2 USING SPECIFIED IMMUNOSORBENT | 2021 |
|
RU2752862C1 |
| METHOD FOR DETERMINING THE ACTIVITY OF NEUTRALISING ANTIBODIES AGAINST SARS-CoV-2 IN THE SERUM OR PLASMA OF PEOPLE WITH PAST CASES OF COVID-19 OR VACCINATED WITH PREVENTIVE VACCINES AGAINST THE NOVEL CORONAVIRUS INFECTION COVID-19 USING A SET OF ENZYME IMMUNOASSAY REAGENTS CONTAINING A RECOMBINANT RECEPTOR-BINDING DOMAIN (RBD) OF SURFACE GLYCOPROTEIN S OF CORONAVIRUS SARS-CoV-2 AND RECOMBINANT HUMAN RECEPTOR ACE2 | 2021 |
|
RU2784655C1 |
| METHOD FOR DETECTING INFECTION OF HUMANS AND ANIMALS WITH SARS CoV 2 AND A DIAGNOSTIC KIT FOR IMPLEMENTING THE METHOD | 2021 |
|
RU2776295C1 |
| POLYPEPTIDE MODULE FOR BINDING CONSERVATIVE EPITOPE OF RECEPTOR-BINDING DOMAIN OF SPIKE PROTEIN OF SARS-CoV-2 CORONAVIRUS | 2022 |
|
RU2809183C1 |
| MONOCLONAL ANTIBODY TO RDB FRAGMENT IN COMPOSITION OF SARS-COV-2 S PROTEIN | 2020 |
|
RU2744274C1 |
| METHOD FOR DETECTING ANTIBODIES - CLASS G IMMUNOGLOBULINS IN BLOOD SERUM TO PATHOGENS OF SEVERE ACUTE RESPIRATORY VIRAL INFECTIONS, INCLUDING SARS-COV-2, WITH SIMULTANEOUS PROGNOSIS OF COVID-19 SEVERITY, BASED ON HYDROGEL BIOCHIP | 2020 |
|
RU2746815C1 |
| BROADLY NEUTRALIZING ANTIBODY AGAINST SARS-CoV-2 | 2022 |
|
RU2810476C1 |
| MONOCLONAL ANTIBODY IC2 AND ITS ANTIGEN-BINDING FRAGMENT, SELECTIVELY BINDING RECEPTOR-BINDING DOMAIN OF SPIKE PROTEIN OF SARS-CoV-2 VIRUS, HAVING VIRUS-NEUTRALIZING ACTIVITY | 2023 |
|
RU2817697C1 |
| SINGLE-DOMAIN NANO-ANTIBODIES AGAINST SPIKE PROTEIN OF SARS-CoV-2 VIRUS | 2021 |
|
RU2794141C2 |
| Method for producing Chinese hamster ovary cell strain, being a producer of recombinant SARS-CoV-2 virus protein RBD, Chinese hamster ovary cell strain, producer of recombinant SARS-CoV-2 protein RBD, method for producing recombinant SARS-CoV-2 virus protein RBD, test system for enzyme immunoassay of human serum or plasma, and use thereof | 2020 |
|
RU2723008C1 |
